News For ZIOP From The Last 14 Days Check below for free stories on ZIOP the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 06:18 EDT |  | ZIOP |
| theflyonthewall.com: | Ziopharm announces positive preliminary OS data | | ZIOPHARM Oncology announced positive preliminary overall survival, OS, data from the Company's randomized, controlled Phase 2 trial of palifosfamide plus doxorubicin vs. doxorubicin alone (PICASSO) in patients with unresectable or metastatic soft tissue sarcoma. :theflyonthewall.com |
|
|
February 12, 2012
|
| 10:38 EDT | | ZIOP |
| theflyonthewall.com: | Jim Cramer's "Mad Money" | | Jim Cramer said win or lose, once the Greece issue is resolved the markets will breath easier, but if Greece defaults or gets kicked out of the eurozone, the market will give back some of its recent gains. Cramer outlined his game plan for the companies reporting the week of Feb. 13. (Monday) Masco (MAS) Cramer would buy shares on any weakness. (Tuesday) recent IPO Michael Kors (KORS) he'd buy on any weakness. Zynga (ZNGA) he'd "ring the register". (Wednesday) John Deere (DE), Devon Energy (DVN) and Goldcorp (GG) - Cramer advised a wait-and-see approach with all three names. (Thursday) General Motors (GM) buy under $22. VF Vorp. (VFC) take profits ahead of their release. (Friday) Cramer said that he's worried about Campbells Soup (CPB) and Heinz (HNZ) and would not be a buyer of either. On the IPO front, Cramer recommended investors buy in on the Brightcove IPO, but all while keeping an eye on the Currency Shares Euro Trust (FXE) to see how the markets are reacting to the latest Greek news. SPECULATION FRIDAY: Cramer returned to Fortinet (FTNT) which is up 208% since his Novermber 2009 recommendation. He said that the cyber-security theme is still in tact, and with hackers getting more sophisticated every day, more and more companies will need Fortinet's unified threat management systems. The shares are expensive trading at 43x earnings with a 21% growth rate. But given the size of the market opportunity, Cramer said it's still worth buying shares on any market pullback. Fortinet recently reported excellent earnings. Given Fortinet's size, Cramer said the company may also be a takeover target someday. For the final "All Request" segment of the week, Cramer responded to a tweet asking him to compare Tempur-Pedic (TPX) and Select Comfort (SCSS) in a battle of the high-end mattress makers. The premium mattress segment is a lucrative one for both companies. Cramer said that Select Comfort, trading at 22x earnings with a 19% growth rate, is by far the better deal. Select Comfort, with only 5% market share, has more room to grow. Its same-store comps rose by a greater percent and it has higher margins than Tempur. MAD MAIL: Cramer was bullish on Optimer Pharmaceuticals (OPTR) as a speculative play but was bearish on KIT Digital (KITD) and Guidewire (GWRE), advising investors to sell now. Cramer said that he's not a buyer of C&J Services (CJES), and prefers Core Labs (CLB) and Schlumberger (SLB), both of which have less natural gas exposure. Cramer said there's no rush to Massimo (MASI) and would wait for a pullback. He also noted that Ziopharm Oncology (ZIOP) is like playing FDA roulette and is not for the faint of heart. Cramer would hold onto Nvidia (NVDA), but admitted the stock is a "wide ride." Cramer said he's not a buyer of Nuance Communications (NUAN). Then, Cramer also clarified his position on Apple (AAPL). He said that yes, Apple is less of a company without founder and visionary Steve Jobs, but that doesn't mean its not still a great company and great stock to own. He said the company's chart says it all. LIGHTNING ROUND: (Bullish) DHR; DSW; ROST; TJX; ISRG; TKR. (Bearish) TSL; ZOLT; AFFY. http://www.thestreet.com/story/11412352/1/cramers-mad-money-recap-next-weeks-game-plan-update-1.html :theflyonthewall.com |
|
|
February 6, 2012
|
| 06:12 EDT | | ZIOP |
| theflyonthewall.com: | Ziopharm announces FDA acceptance of IND for oral palifosfamide | | ZIOPHARM Oncology announced that the U.S. Food and Drug Administration, FDA, has accepted its investigational new drug, IND, application for the oral dosing of palifosfamide (ZymafosŪ or ZIO-201), a form of administration offering several potential patient-oriented advantages and an outpatient treatment for expanded global commercial reach. :theflyonthewall.com |
|
|
January 30, 2012
|
| 06:57 EDT | | ZIOP |
| theflyonthewall.com: | Ziopharm announces IDMC recommends continuation of Phase lll study | | ZIOPHARM Oncology announced that the Independent Data Monitoring Committee, IDMC, has unanimously recommended continuation of the international, randomized, double-blinded, placebo-controlled Phase 3 trial, PICASSO 3, of palifosfamide (ZymafosŪ or ZIO-201) in front-line metastatic soft tissue sarcoma. The IDMC reviewed all available study data and determined that the trial should continue as designed and conducted, which is the third such review and recommendation by the committee. Targeted completion of enrollment for PICASSO 3 is expected by the end of the first quarter of 2012. The outcome in progression-free survival, the study's primary endpoint for accelerated approval, is anticipated in the second half of 2012. :theflyonthewall.com |
|
|
|
